// App-Quantinova.ai

8517 : Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

Researchers

Presenter

  • Davina Gale

Principal Investigators

  • Katrin Heider

  • Malcolm Perry

  • Giovanni Marsico

  • Andrea Ruiz-Valdepeas

  • Viona Rundell

  • Jerome Wulff

  • Garima Sharma

  • Karen Howarth

  • David Gilligan

  • Susan Harden

  • Doris M. Rassl

  • Robert Rintoul

  • Nitzan Rosenfeld

Medical Centers

  • Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom

  • Inivata, Cambridge, United Kingdom

  • Cambridge Clinical Trials Unit Cancer Theme, Cambridge, Cambridgeshire, United Kingdom

  • Addenbrookes Hospital, Cambridge, United Kingdom

  • Papworth Hospital, Cambridge, United Kingdom

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • Inivata Ltd

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Transcription factor Maf

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT04153526

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved